Skip to main content
  • In conjunction with the American Uveitis Society

    Uveitis 2024: Rising to New Heights

    Take a deep dive into the current research and challenges in the diagnosis and management of uveitis and ocular inflammatory diseases including new approaches, tools and standards of care.

    Friday, Oct. 18
    McCormick Place, Chicago, IL

    Breakfast will be served for in-person attendees at 7 a.m. Pacific Daylight Time. The program will start at 8 a.m. Pacific Daylight Time.

    Program Directors

    Lucia Sobrin, MD
    Ann-Marie Lobo-Chan, MD, MS

    Program Planning Group

    Lucia Sobrin, MD
    Ann-Marie Lobo-Chan, MD, MS
    Edmund Tsui, MD
    Wendy Smith, MD
    Stephanie Llop Santiago, MD
    Jessica Shantha, MD
    Eduardo Uchiyama, MD

    Mission Statement

    The mission of the 2024 Uveitis Subspecialty Day is to provide attendees with a comprehensive, state-of-the-art update on the diagnosis and management of uveitis.

    Target Audience

    The intended audience for this program includes general ophthalmologists, comprehensive ophthalmologists, uveitis specialists, other ophthalmologic subspecialists (cornea, retina, etc.), and allied health personnel who are involved in the management of patients with uveitis and ocular inflammatory diseases.

    Education Level

    Intermediate, Advanced

    Program Objectives

    Upon completion of this activity, participants should be able to:

    • Identify the various forms of ocular inflammatory diseases, including retinal vasculitis, and anterior, intermediate, and posterior uveitis.

    • Construct a differential diagnosis for various forms of uveitis.

    • Classify the principles of diagnosis for ocular inflammatory disorders in order to initiate appropriate disease-directed evaluations.

    • Identify the important and appropriate role of immunomodulatory therapy for patients with specific ocular inflammatory diseases and also for patients with steroid-dependent inflammation.

    • Describe potential new diagnostic and treatment modalities for uveitis and ocular inflammatory diseases, including selected therapeutic agents in development.